Reported about 1 month ago
In a market viewed as overly expensive, three analysts from The Motley Fool recommend considering Axsome Therapeutics, CRISPR Therapeutics, and Pfizer as potential bargain stocks. Despite the high price levels in the market, these companies possess significant growth potential and promising developments in their respective fields. Axsome Therapeutics is nearing regulatory approval for migraine and fibromyalgia treatments, while CRISPR Therapeutics recently received FDA approval for a gene-editing therapy. Pfizer, although recovering from declines in its COVID-19 vaccine sales, is seeing growth from new product acquisitions and a rebuilding pipeline, making these stocks worth evaluating for investors.
Source: YAHOO